SEC Form 4 · accession 0001140361-26-028846
Lyell Immunopharma, Inc. · LYEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Jul 16, 2026
Accepted (ET)
Jul 17, 2026 · 9:45 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001806952
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 16, 2026 | S | 10 | $13.73 | D | 2,857,490 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.